Combination of γ-interferon with trail and cisplatin or etoposide induces apoptosis in human neuroblastoma cell line SH-SY5Y

Chinese Medical Sciences Journal

Volumn 22, Issue 1, 2007, Pages 38-43

  Tong, Hai Xia ^a   Lu, Chun Wei ^a   Zhang, Ji Hong ^a   Li, Ma ^a   Zhang, Jin Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

interferon; Apoptosis; Neuroblastoma; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CASPASE 8; CASPASE 8 INHIBITOR; CISPLATIN; ETOPOSIDE; GAMMA INTERFERON; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; ETOPOSIDE; HUMANS; INTERFERON-GAMMA; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34247357278     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Griffith TS, Anderson RD, Davidson BL, et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165:2886-94.
2. Fulda S, Debatin KM. IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002; 21:2295-308.
3. 2 also contributes to TRAIL resistance in NB. Cancer Res 2003; 63:1122-9.
4. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005; 228:133-41.
5. Johnsen J, Pettersen I, Ponthan F, et al. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-γ and TRAIL. Int J Oncol 2004; 25: 1849-57.
6. Nosel MM, Pieters R, Voute PA, et al. The N-myc paradox: N-myc overexpression in neuroblastoma is associated with sensitivity as well as resistance to apoptosis. Cancer Lett 2003; 197: 165-72.
7. Kim Y, Suh N, Sporn M, et al. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277:22320-9.
8. Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002; 99:491-504.
9. Wang MJ, Liu YX, Li XL, et al. Chemotherapeutic drugs enhanced rsTRAIL tumoricidal activity. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004; 26:524-8.
10. Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-53.
11. Guan B, Yue P, Clayman GL, et al. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001; 188:98-105.
12. Xiang H, Fox JA, Totpal K, et al. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 2002; 21:3611-9.
13. Muhlethaler-Mottet A, Balmas K, Auderset K, et al. Restoration of TRAIL-induced apoptosis in a caspase-8-deficient neuroblastoma cell line by stable re-expression of caspase-8. Ann N Y Acad Sci 2003; 1010:195-9.
14. Muhlethaler-Mottet A, Bourloud KB, Auderset K, et al. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Oncogene 2004; 23:5415-25.
15. Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850-61.